Suraksha Diagnostic Limited — PPTs, 21-05-2026: Investor Presentation

**Business Performance:** Suraksha Diagnostic reported robust FY26 results: revenue surged 23% YoY to ₹313.6 Cr, and EBITDA grew 16% to ₹98.6 Cr. Q4 showed strong momentum, with revenue up 25% to ₹82.2 Cr and EBITDA climbing 26% to ₹25.2 Cr, driven by core diagnostics and new center ramp-ups. FY26 Profit After Tax rose 1% to ₹31.4 Cr (Q4 PAT down 14% to ₹6.2 Cr due to investments). Mature centers maintain strong 36-37% EBITDA margins.

**Strategy & Outlook:** The company targets aggressive organic and inorganic expansion in Eastern and North-Eastern India. Management prioritizes boosting throughput from new centers, improving cost efficiencies, and enhancing service capabilities via technology and B2B partnerships. The goal is sustained healthy growth and progressive margin enhancement.

**Recent Developments:** Suraksha added 20 new diagnostic centers since its December 2024 listing. Recent updates include a 63% stake acquisition in Fetomat Wellness (fertility clinics) and the launch of Suraksha Genomics for advanced genetic testing. The CMC facility also upgraded with new 1.5 Tesla Helium-Free MRI technology.